ESTRO 2024 - Abstract Book

S5703

RTT - Patient experience and quality of life

ESTRO 2024

Keywords: Paediatrics, Awake, Brain

References:

www.larsenspride.co.uk/radiotherapy-resources

2352

Digital Poster

USES OF SUPPLEMENTS IN RADIOTHERAPY,L-GLUTAMINE FOR THE PREVENTION AND IMPROVEMENT OF ORAL MUCOSITIS

Maria C Cruz miñoz 1 , Africa Fernández Forné 2 , Ana Torres García 1

1 Hospital punta europa, Oncologia radioterapica, Algeciras, Spain. 2 Hospital Quirón salud malaga, Oncología radioterapica, Malaga, Spain

Purpose/Objective:

The objective of this study is to analyze the administration of oral L-glutamine in daily clinical practice to prevent severe oral mucositis in head and neck cancer (HNC) patients. As secondary end point we analyzed the use of major opioids.

Material/Methods:

From November 2018 to April 2023 we retrospectively analyzed 75 patients with HNC treated in our center who were administered oral L-glutamine (14g/8hour/day) during treatment. All patients received radiotherapy (RT) ± concomitant chemotherapy (QT). The CTCAE v5.0 scale was used to assess acute toxicity. With a mean follow-up of 19 months, all patients have well tolerated L-glutamine, only 4 patient reduced dose (metallic taste and itchy). L-glutamine was initiated at a median of 15 days prior to RT±QT. Our cohort included 75% men and 25% women, median age 62 years [37-87], 84% locally advanced stage, 86% squamous histology and most frequent locations were larynx 26.3% and oral cavity 24.7%. Mean radiation dose was 66Gy [57,5-69,96] and 70% received concomitant RTQT.

Results:

Severe oral mucositis was observed in <30% of patients at completion of RT±QT, at first month only 3% remained and at third month we did not observe any (Graphic-1). 48% patients required major opioid treatment for pain relieve, starting at a median cumulative dose of 40Gy. Only eight patients required hospital admission.

Conclusion: